ArticleClinical and experimental nephrology2024
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Erratum issuedAbstract read
In one paragraph
Article in Clinical and experimental nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Long-term impact of diverting ileostomy after stoma closure on the renal function and risk factors for chronic kidney disease following colorectal tumor surgery.Surgery today · 2026Article
- Predictions of cisplatin-induced hyponatremia in patients with malignancy: a retrospective cohort survey of all cisplatin administration in clinical practice.Clinical and experimental nephrology · 2026Article
- Incidence of renal injury following chemotherapy in malignant tumor patients and analysis of associated factors.Frontiers in medicine · 2026Article
- Article
- Development and validation of an algorithm for identifying patients undergoing dialysis from patients with advanced chronic kidney disease.Clinical and experimental nephrology · 2025Article
- Reassessing Cisplatin Eligibility in Urothelial Carcinoma: A Retrospective Study on Dose Reduction Strategies.Cureus · 2025Article
- Prediction of Cisplatin-Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information.Clinical and translational science · 2025Article
- Stratification system for pharmaceutical care in cancer patients: Chinese expert consensus.Frontiers in pharmacology · 2025Article
- Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review.International cancer conference journal · 2024Article
- Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review.Cancer diagnosis & prognosisReview
Corrections and comments
- Erratum issued
Authors and funding
36 authors.
Motoko YanagitaDepartment of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan. motoy@kuhp.kyoto-u.ac.jp.
Satoru MutoDepartment of Urology, Graduate School of Medicine, Juntendo University, Bunkyo City, Tokyo, Japan.
Hiroyuki NishiyamaDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yuichi AndoDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Sumio HirataDepartment of Academic Education, I and H Co., Ltd, Ashiya, Japan.
Kent DoiDepartment of Emergency and Critical Care Medicine, The University of Tokyo Hospital, Bunkyo City, Tokyo, Japan.
Yutaka FujiwaraDepartment of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan.
Norio HanafusaDepartment of Blood Purification, Tokyo Women's Medical University, Shinjuku City, Tokyo, Japan.
Takahiro HattaDepartment of Respiratory Medicine, Anjo Kosei Hospital, Anjo, Japan.
Junichi HoshinoDepartment of Nephrology, Tokyo Women's Medical University, Shinjuku City, Tokyo, Japan.
Satoko IchiokaDepartment of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan.
Takamitsu InoueDepartment of Renal and Urologic Surgery, International University of Health and Welfare Narita Hospital, Chiba, Japan.
Kenji IshikuraDepartment of Pediatrics, Kitasato University School of Medicine, Minato, Kanagawa, Japan.
Taigo KatoDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Hiroshi KitamuraDepartment of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Yusuke KobayashiDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Minato, Tokyo, Japan.
Yuichi KoizumiDepartment of Pharmacy, Seichokai Fuchu Hospital, Izumi, Japan.
Chihiro KondohDepartments of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takeshi MatsubaraDepartment of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kazuo MatsubaraDepartment of Pharmacy, Wakayama Medical University Hospital, Wakayama, Japan.
Koji MatsumotoHyogo Cancer Center, Akashi, Hyogo, Japan.
Yusuke OkudaDepartment of Pediatrics, Kitasato University School of Medicine, Minato, Kanagawa, Japan.
Yuta OkumuraDepartment of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Yugo ShibagakiDivision of Nephrology and Hypertension, Department of Internal Medicine, Saint Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Hideki ShimodairaDivision of Medical Oncology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Nao TakanoDepartment of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.
Akiko UchidaDepartment of Nursing, Seirei Sakura Citizen Hospital, Chiba, Japan.
Kimikazu YakushijinDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Hyogo, Japan.
Takehito YamamotoDepartment of Pharmacy, The University of Tokyo Hospital, Bunkyo City, Tokyo, Japan.
Kazuhiro YamamotoDepartment of Pharmacy, Kobe University Hospital, Kobe, Japan.
Yoshinari YasudaDepartment of Nephrology, Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mototsugu OyaDepartment of Urology, Keio University School of Medicine, Minato, Tokyo, Japan.
Hirokazu OkadaDepartment of Nephrology, Saitama Medical University, Saitama, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo, Bunkyo City, Tokyo, Japan.
Naoki KashiharaDepartment of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Acute Kidney InjuryAntineoplastic AgentsHumansPractice Guidelines as TopicAntineoplastic AgentsAcute kidney injuryAnticancer drug therapyCancer survivorsGlomerular filtration rateImmune checkpoint inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.